Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
27.39
-0.38 (-1.37%)
At close: Mar 16, 2026, 4:00 PM EDT
26.86
-0.53 (-1.94%)
After-hours: Mar 16, 2026, 7:17 PM EDT
Enliven Therapeutics Employees
Enliven Therapeutics had 60 employees as of December 31, 2025. The number of employees decreased by 2 or -3.23% compared to the previous year.
Employees
60
Change
-2
Growth
-3.23%
Revenue / Employee
n/a
Profits / Employee
-$1,728,233
Market Cap
1.64B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 60 | -2 | -3.23% |
| Sep 30, 2025 | 65 | 8 | 14.04% |
| Jun 30, 2025 | 63 | 11 | 21.15% |
| Mar 31, 2025 | 65 | 15 | 30.00% |
| Dec 31, 2024 | 62 | 16 | 34.78% |
| Sep 30, 2024 | 57 | 13 | 29.55% |
| Jun 30, 2024 | 52 | 15 | 40.54% |
| Mar 31, 2024 | 50 | 21 | 72.41% |
| Dec 31, 2023 | 46 | 17 | 58.62% |
| Sep 30, 2023 | 44 | 20 | 83.33% |
| Jun 30, 2023 | 37 | 13 | 54.17% |
| Mar 31, 2023 | 29 | - | - |
| Sep 30, 2022 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Sarepta Therapeutics | 835 |
| Novavax | 749 |
| Agios Pharmaceuticals | 540 |
| Vericel | 398 |
| Harmony Biosciences Holdings | 293 |
| Zymeworks | 264 |
| Innoviva | 159 |
ELVN News
- 19 days ago - Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - PRNewsWire
- 2 months ago - Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars - Benzinga
- 2 months ago - Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones - PRNewsWire
- 2 months ago - Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development - PRNewsWire
- 3 months ago - Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - PRNewsWire
- 3 months ago - Enliven Therapeutics Announces New CEO to Drive Next Phase of Development - PRNewsWire
- 4 months ago - Enliven Therapeutics: Notable Early Signals, But Too Many Assumptions To Justify A Buy - Seeking Alpha
- 4 months ago - Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PRNewsWire